-
Fudan Zhangjiang: Taizhou Fudan Zhangjiang obtained the registration certificate of parecoxib sodium for injection
Time of Update: 2021-07-23
On February 25, Fudan Zhangjiang announced that the company’s wholly-owned subsidiary, Taizhou Fudan Zhangjiang, recently received the "Drug Registration Certificate" for parecoxib sodium for injection approved and issued by the State Food and Drug Administration .
-
The first wave of salary adjustments and employee optimization plans for pharmaceutical companies in 2021 are exposed!
Time of Update: 2021-07-23
It is reported that in January 2021, the French pharmaceutical giant Sanofi announced a layoff plan-the company will lay off 400 employees in the R&D department in France in the next three years.
-
Innovent announces that the Phase I clinical study of anti-CD47/PD-L1 bispecific antibody has completed the first foreign patient administration
Time of Update: 2021-07-23
Cinda Biopharmaceuticals, a biopharmaceutical company dedicated to the development, production and sales of innovative drugs for the treatment of tumors, autoimmune, metabolic diseases and other major diseases, today announced its potential first anti-CD47/PD-L1 bispecific antibody (R&D code: IBI322) Phase I clinical study completed the first foreign patient drug administration .
-
Kelun Pharmaceutical: Metronidazole and Sodium Chloride Injection, Fat Emulsion Injection (C14~24) Review
Time of Update: 2021-07-23
Fat emulsion injection (C14~24) passed the consistency evaluation and obtained the approval notice of drug supplement application, which is mainly used for parenteral nutrition to supplement energy and essential fatty acids .
-
Genting Sunshine is included as a constituent stock of several indexes of Hang Seng Index Co., Ltd.
Time of Update: 2021-07-23
The Hang Seng Healthcare Index provides a market reference index that reflects the overall performance of securities listed in Hong Kong and mainly engaged in healthcare services .
-
Roche antibody cocktail therapy for mild to moderate COVID-19 patients recommended by EMA
Time of Update: 2021-07-23
On February 26, Roche announced that the European Medicines Agency (EMA) Committee for Human Uses (CHMP) has issued scientific opinions to support the use of experimental antibody cocktail therapy casirivimab and imdevimab as treatment options for confirmed COVID-19 patients.
-
Junshi Biotech and AstraZeneca announce a commercialization strategic cooperation on triprolizumab
Time of Update: 2021-07-23
Junshi Biotechnology and AstraZeneca will continue to explore overseas business cooperation including emerging markets, and actively explore the possibility of expanding the depth and breadth of future cooperation on the basis of existing cooperation, and work together to create multi-pipeline cooperation between multinational pharmaceutical companies and local pharmaceutical companies It is a model for jointly promoting Chinese local innovative drugs to go abroad and benefit patients all over the world .
-
Explore hearing solutions for 40 years Cochlear helps people listen to the world
Time of Update: 2021-07-23
Cochlear has been actively fulfilling its corporate mission: to help people listen to sounds and be heard at the same time; to help people rebuild communication bridges and enjoy a complete life; to change the public's perception of hearing loss and effective interventions; through continuous efforts Innovations bring users hearing solutions that make them long-lasting benefits .
-
Haisco: Signed a cooperation agreement for olanzapine transdermal patch
Time of Update: 2021-07-23
Starton awarded Haisco with its research on a weekly olanzapine transdermal drug delivery system, a product intended to be used for nausea and vomiting caused by tumor chemotherapy STAR-OLZ has the exclusive right to develop, register and commercialize STAR-OLZ in mainland China .
-
Pfizer, Novartis, Sanofi, Takeda, Teva and many other rare disease new drugs have been listed in China and have been included in medical insurance
Time of Update: 2021-07-23
February 28, International Rare Disease Day . In recent years, China has introduced a series of favorable policies to bring good news to nearly 20 million patients with rare diseases in China. Dom
-
Pfizer Biologics Etanercept Enters the National Medical Insurance List
Time of Update: 2021-07-23
In addition, the Sichuan Provincial Medical Security Bureau and Sichuan Provincial Department of Human Resources and Social Security also issued the "Notice on Issues Concerning the Implementation of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" on February 5.
-
Suqiao Biotech's partner Cinda Biotech's new crown antibody project was approved by the U.S. FDA IND
Time of Update: 2021-07-23
Warm congratulations on this project entering a new stage, and we also look forward to continuing to provide high quality for Cinda Biologics and other innovative biopharmaceutical companies And fast CMC service .
-
Nuocheng Jianhua's new TYK2 inhibitor ICP-332 new drug research application was accepted by the State Food and Drug Administration
Time of Update: 2021-07-23
On February 26, 2021, the biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) announced that the company's new tyrosine kinase 2 (Tyrosine Kinase 2, TYK2) inhibitor ICP-332 new drug research ( IND) application was accepted by the National Medical Products Administration (NMPA) .
-
The main contents of the "Blue Book of Health Insights on Patients with Multiple Sclerosis in China" released in Beijing
Time of Update: 2021-07-23
On the eve of the International Rare Disease Day on February 28, in order to understand the real treatment data of patients with multiple sclerosis and the status of standardized treatment of patient
-
Nuocheng Jianhua appoints Dr. Xiangyang Zhang as Chief Medical Officer
Time of Update: 2021-07-23
Xiangyang Zhang, who has extensive clinical and new drug development experience in the field of biomedicine, as the chief medical officer and co-founder of Nuocheng Jianhua , Chairman and CEO Dr.
Zhang Xiangyang's office in the United States further demonstrates Nuocheng Jianhua's commitment to global development .
-
Fuan Pharmaceutical's Esomeprazole Sodium for Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-07-23
On March 1, Fuan Pharmaceutical issued an announcement stating that its subsidiary, Hubei People’s Pharmaceutical, had recently received a drug supplement application approval notice issued by NMPA,
-
Corder Rare Disease Center and Story FM launches "Rare Cafe" Story Salon
Time of Update: 2021-07-23
Tang Fenglei, representative of patients with Fabry disease "Since the age of eighteen, my hands, feet, face, and body have had edema without warning, and my abdomen often suffers from unexplained pain.
-
Deck Pharmaceuticals (6996.HK) was included in nine benchmark and thematic indexes including the Hang Seng Composite Index
Time of Update: 2021-07-23
The Hang Seng Southbound Stock Connect Index reflects the overall performance of Hong Kong Main Board-listed securities that can be invested through Southbound Stock Connect channels .
-
Hebo Medicine's new generation of anti-CTLA-4 antibody HBM4003 has made new progress
Time of Update: 2021-07-23
Hebo Pharmaceutical announced today that the National Medical Products Administration (NMPA) approved its research product anti-CTLA-4 fully human monoclonal heavy chain antibody HBM4003 and PD-1 antibody/chemotherapy for the treatment of advanced non-small cell lung cancer and other solid tumors Patient's clinical trial application .
-
Weijian Pharmaceutical and German Marksman once again signed a contract with Yabos to benefit domestic patients with hepatic encephalopathy
Time of Update: 2021-07-23
On February 26, 2021, Hong Kong Weijian Pharmaceutical Group and the German Max Pharmaceutical Factory announced a strategic cooperation .
The strategic cooperation between the two sides, marking the Victoria Health Medical German Maxwell's significant products Ya Division ® (ornithine aspartate) commercial interests in China .
